Scancell Acquires Neuphoria in All-Share Merger, Plans Nasdaq Listing Under SCLT
The merged company will list on Nasdaq as SCLT and raise up to $89M to fund Phase 3 of its melanoma immunotherapy iSCIB1+.
/ 1648 items
#XY↓
Oppenheimer Initiates Outperform Coverage on Palisade Bio with $8 Price Target
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
Arrowhead’s Plozasiran Cuts Acute Pancreatitis Risk by Up to 100% in Phase 3 Severe Hypertriglyceridemia Trials
Arrowhead plans sNDA filing by end of 2026.
Repligen Acquires BioLife Solutions for $1.5 Billion to Strengthen Cell and Gene Therapy Leadership
Repligen to acquire BioLife Solutions in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026.
Dyne Therapeutics Prices Upsized $375 Million Public Offering to Fuel Muscle Disease Pipeline
Dyne Therapeutics announced the pricing of an upsized $375 million public stock offering at $20.50 per share to advance DMD and DM1 programs and extend cash runway into 2029.
Celldex Discontinues Barzolvolimab Development in Prurigo Nodularis After Phase 2 Failure
Celldex discontinues barzolvolimab development in prurigo nodularis after its Phase 2 study failed to meet the primary endpoint and key secondary endpoints.